Skip to content
DataLookout
Menu

NCT05588141

000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 211 versions: 8 with changes below, 42 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria changed
    • Enrollment increased: 96 → 106 participants
  2. Minor Enrollment target: 96 to 106
    • Site details revised at 1 of 2 sites
  3. Notable Eligibility criteria revised
  4. Notable Eligibility criteria shortened, about 2 words
    • Study sites: 1 to 2
  5. Minor Study title expanded, about 1 word
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Eligibility criteria expanded, about 13 words Show 4 more changesShow less
    • Primary endpoints: details revised at 1 of 2 entries
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study description expanded, about 17 words
    • Publications: details revised at 5 of 5 entries
  2. Notable Eligibility criteria expanded, about 12 wordsv183
  3. Notable Primary completion date: Aug 1, 2025 to Aug 1, 2028
    • Study completion date: Aug 2, 2029 to Aug 2, 2032
    v173
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To determine 12 months PFS in participants w/ recurrent glioma, IDH1/2-mutant, WHO grade 3 treated w/ zotiraciclib in comparison w/ the established brain tumor database matched for tumor molecular characteristics and clinical prognostic factors
Timeframe: 12 Months
To estimate recommended phase II dose (RP2D) of zotiraciclib
Timeframe: 28 days

Secondary (3)

To determine the efficacy of treatment with zotiraciclib in participants with recurrent glioma, IDH1/2-mutant WHO grade 3 in comparison with the established brain tumor database by 3 years PFS rate
To determine the safety of zotiraciclib in participants with recurrent glioma, IDH1/2-mutant WHO grades 2-4
To determine the efficacy of treatment with zotiraciclib in participants with recurrent glioma, IDH1/2-mutant WHO grade 3 in comparison with the established brain tumor database by 5 years overall survival (OS) rate

Arms and interventions

1 (Closed to Enrollment)Experimental

Escalation/de-escalation dose levels of zotiraciclib given in 28 day cycles

2Experimental

Estimated RP2D of zotiraciclib given in 28 day cycles

3Experimental

One RP2D dose of zotiraciclib given on the day prior to brain tumor biopsy or resection, a continuation of treatment with estimated RP2D of zotiraciclib given in 28 days cycles following the recovery of the surgery

Drugs: Zotiraciclib

Sites

2 sites in 1 country